Tampa, Florida–(Newsfile Corp. – November 2, 2021) – Psilera Inc., a leading biotechnology company leveraging computational chemistry to develop non-hallucinogenic new chemical entities and outpatient delivery mechanisms based on dimethyltryptamine (DMT) formulations, will be attending the Wonderland Miami Conference by Microdose. Dr. Jackie von Salm, Psilera Co-Founder and Chief Scientific Officer, will be speaking on the Next-Generation Psychedelics panel live on Monday November 8th at 3:10 pm ET.
“The opportunity to speak on next-generation psychedelics is particularly exciting, as we have positioned ourselves as pioneers in drug development of novel psychedelic-like compounds,” says Dr. von Salm. “Our greatest goal is to expand access to these medicines beyond the current psychedelic model.”
For more information about the conference or to register to attend, click here.
About Psilera – Psilera Inc. is a psychedelic-based biotechnology company developing its proprietary neuromodulator pipeline to target mental health disorders. With a proven and award-winning executive team, Psilera leverages research strengths from the pharmaceutical and cannabis industries to repurpose psychoactive natural products into patient-centric treatments. New formulations tailoring the therapeutic effects of DMT will improve treatment scalability and patient compliance further expanding addressable markets. Psilera’s technology platform (BRAIN) will identify next-generation compounds with modified psychedelic and therapeutic effects in the areas of mood, cognitive, and substance use disorders.
About Wonderland – Wonderland by Microdose Psychedelic Insights in Miami will offer the industry a unique in-person convergence of business, science, music, and emerging technologies. The event is a thought-leadership platform and an opportunity to connect with influential leaders in science, policy, and business. It will also act as a launching pad for innovative content connected to the psychedelic medicine space, providing compelling entertainment and collaboration opportunities for attendees.
Psilera Bioscience contact details
Chris Witowski, PhD
Co-Founder and CEO
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101482